Although the prostate-specific antigen (PSA) test is widely used to clinically screen men for prostate cancer, and is known to be a sensitive marker for monitoring cancer progression, it also provides only limited information on the presence of bone metastasis in patients [35]. The gene discussed is KLK3; the disease is prostate carcinoma.